JMIR Cancer - Search

View query in Help articles search

Field

e.g. mhealth

Operator

Field

Criteria

e.g. John Smith or 0000-0001-6479-5330

Exact Match for Criteria

Yes No

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS

Sort by:

Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study

All 86 patients using version 1 of the app were treated for early stage disease, and two-thirds (n=54, 63%) of these patients were treated in an adjuvant setting. In contrast, about half (n=56, 53%) of the patients using version 2 of the app received treatment for advanced disease with noncurative intention.

Andreas Trojan, Basil Bättig, Meinrad Mannhart, Burkhardt Seifert, Mathis N Brauchbar, Marco Egbring

JMIR Cancer 2021;7(1):e26950

Download Citation: END BibTex RIS

Download PDF Download XML

A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

The most frequent chemotherapy regimen in all groups was epirubicin/cyclophosphamide (n=32), followed by paclitaxel/trastuzumab (control: n=8; app: n=4; app and physician: n=7), and paclitaxel/carboplatin (control: n=4; app: n=8; app and physician: n=7). In total, six different chemotherapy regimens were reported using seven distinct chemotherapeutic agents. The median observation interval between visit 1 and visit 2 (IQR 6), and also between visit 2 and visit 3 (IQR 8), was 21 days.

Marco Egbring, Elmira Far, Malgorzata Roos, Michael Dietrich, Mathis Brauchbar, Gerd A Kullak-Ublick, Andreas Trojan

J Med Internet Res 2016;18(9):e238

Download Citation: END BibTex RIS

Download PDF Download XML

Search Articles

Search Results (1 to 2 of 2 Results)